Johnny Slot Email

Director Manufacturing . MIMETAS

Current Roles

Employees:
136
Revenue:
$23.1M
About
High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
MIMETAS Address
De Limes 7
Leiden, null
Netherlands
MIMETAS Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.